Skip to main content

Closed

CLDI: Calidi Biotherapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+0.0% / yr

Operating margin0.0%

ROIC-266.8%

Financially safe

Stretched

Debt / equity0.46×

Interest coverage-111.9×

Current ratio1.92×

Calidi Biotherapeutics, Inc.

CLDINew York Stock Exchange Arca·USD·Closed

Calidi Biotherapeutics, Inc.

CLDINew York Stock Exchange Arca·USD·Closed

$1.89

+12.50%

$1.89

+$0.21 (12.50%)

52W Range

0thpctl

Volume

0.77×avg

Mkt Cap

870226USD

P/E

-0.0TTM

Div Yield

–ann

52W Range

0thpctl

Volume

0.77×avg

Market Cap

870226USD

P/E Ratio

-0.0TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings